Neoadjuvant relatlimab and nivolumab in resectable melanoma (vol 611, pg 155, 2022)

被引：1
|
作者：
Amaria, Rodabe N.
Postow, Michael
Burton, Elizabeth M.
Tetzlaff, Michael T.
Ross, Merrick I.
Torres-Cabala, Carlos
Glitza, Isabella C.
Duan, Fei
Milton, Denai R.
Busam, Klaus
Simpson, Lauren
McQuade, Jennifer L.
Wong, Michael K.
Gershenwald, Jeffrey E.
Lee, Jeffrey E.
Goepfert, Ryan P.
Keung, Emily Z.
Fisher, Sarah B.
Betof-Warner, Allison
Shoushtari, Alexander N.
Callahan, Margaret
Coit, Daniel
Bartlett, Edmund K.
Bello, Danielle
Momtaz, Parisa
Nicholas, Courtney
Gu, Aidi
Zhang, Xuejun
Korivi, Brinda Rao
Patnana, Madhavi
Patel, Sapna P.
Diab, Adi
Lucci, Anthony
Prieto, Victor G.
Davies, Michael A.
Allison, James P.
Sharma, Padmanee
Wargo, Jennifer A.
Ariyan, Charlotte
Tawbi, Hussein A.
机构：
来源：
NATURE | 2023年 / 615卷 / 7953期
基金：
美国国家卫生研究院;
关键词：
D O I：
10.1038/s41586-023-05892-1
中图分类号：
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号：
07 ; 0710 ; 09 ;
摘要：
引用
收藏
页码：E23 / E23
页数：1
相关论文
共 50 条
  • [11] Neoadjuvant and adjuvant nivolumab (nivo) with anti-LAG3 antibody relatlimab (rela) for patients (pts) with resectable clinical stage III melanoma.
    Amaria, Rodabe Navroze
    Postow, Michael A.
    Tetzlaff, Michael T.
    Ross, Merrick I.
    Glitza, Isabella Claudia
    McQuade, Jennifer Leigh
    Wong, Michael K. K.
    Gershenwald, Jeffrey E.
    Goepfert, Ryan
    Keung, Emily Zhi-Yun
    Fisher, Sarah B.
    Milton, Denai R.
    Patel, Sapna Pradyuman
    Diab, Adi
    Simpson, Lauren
    Davies, Michael A.
    Wargo, Jennifer Ann
    Burton, Elizabeth M.
    Ariyan, Charlotte Eielson
    Tawbi, Hussein Abdul-Hassan
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [12] Neoadjuvant Pepinemab in Combination with Nivolumab and/ or Ipilimumab in Resectable Stage III Melanoma
    Lowe, Michael C.
    Olson, Brian
    Yushak, Melinda
    Mallow, Crystal
    Reilly, Christine
    Hammons, Jacklyn
    Burns, Brian
    Mokhtari, Ali
    Parker, Doug
    Fisher, Terry
    Evans, Elizabeth
    Paulos, Chrystal
    Delman, Keith
    Lesinski, Gregory
    ANNALS OF SURGICAL ONCOLOGY, 2023, 30 (SUPPL 1) : S5 - S5
  • [13] Neoadjuvant Nivolumab and Ipilimumab for Resectable Stage III Melanoma: The New Standard of Care?
    Miura, John T.
    Karakousis, Giorgos C.
    ANNALS OF SURGICAL ONCOLOGY, 2025, 32 (03) : 1394 - 1396
  • [14] Neoadjuvant nivolumab with or without relatlimab in resectable non-small-cell lung cancer: a randomized phase 2 trial
    Schuler, Martin
    Cuppens, Kristof
    Ploenes, Till
    Wiesweg, Marcel
    Du Pont, Bert
    Hegedus, Balazs
    Koester, Johannes
    Mairinger, Fabian
    Darwiche, Kaid
    Paschen, Annette
    Maes, Brigitte
    Vanbockrijck, Michel
    Laehnemann, David
    Zhao, Fang
    Hautzel, Hubertus
    Theegarten, Dirk
    Hartemink, Koen
    Reis, Henning
    Baas, Paul
    Schramm, Alexander
    Aigner, Clemens
    NATURE MEDICINE, 2024, 30 (06) : 1602 - 1611
  • [15] Neoadjuvant nivolumab or nivolumab plus LAG-3 inhibitor relatlimab in resectable esophageal/gastroesophageal junction cancer: a phase Ib trial and ctDNA analyses
    Kelly, Ronan J.
    Landon, Blair V.
    Zaidi, Ali H.
    Singh, Dipika
    Canzoniero, Jenna V.
    Balan, Archana
    Hales, Russell K.
    Voong, K. Ranh
    Battafarano, Richard J.
    Jobe, Blair A.
    Yang, Stephen C.
    Broderick, Stephen
    Ha, Jinny
    Marrone, Kristen A.
    Pereira, Gavin
    Rao, Nisha
    Borole, Aryan
    Karaindrou, Katerina
    Belcaid, Zineb
    White, James R.
    Ke, Suqi
    Amjad, Ali I.
    Weksler, Benny
    Shin, Eun Ji
    Thompson, Elizabeth
    Smith, Kellie N.
    Pardoll, Drew M.
    Hu, Chen
    Feliciano, Josephine L.
    Anagnostou, Valsamo
    Lam, Vincent K.
    NATURE MEDICINE, 2024, 30 (04) : 1023 - +
  • [16] Is Neoadjuvant Therapy Needed in Patients with Resectable Pancreatic Cancer? (vol 16, pg 3, 2022)
    Kim, Dong Uk
    GUT AND LIVER, 2023, 17 (02) : 343 - 343
  • [17] Neoadjuvant nivolumab or nivolumab plus LAG-3 inhibitor relatlimab in resectable esophageal/gastroesophageal junction cancer: a phase Ib trial and ctDNA analyses
    Ronan J. Kelly
    Blair V. Landon
    Ali H. Zaidi
    Dipika Singh
    Jenna V. Canzoniero
    Archana Balan
    Russell K. Hales
    K. Ranh Voong
    Richard J. Battafarano
    Blair A. Jobe
    Stephen C. Yang
    Stephen Broderick
    Jinny Ha
    Kristen A. Marrone
    Gavin Pereira
    Nisha Rao
    Aryan Borole
    Katerina Karaindrou
    Zineb Belcaid
    James R. White
    Suqi Ke
    Ali I. Amjad
    Benny Weksler
    Eun Ji Shin
    Elizabeth Thompson
    Kellie N. Smith
    Drew M. Pardoll
    Chen Hu
    Josephine L. Feliciano
    Valsamo Anagnostou
    Vincent K. Lam
    Nature Medicine, 2024, 30 : 1023 - 1034
  • [18] Integrated biomarker study of neoadjuvant pepinemab and nivolumab in patients with resectable metastatic melanoma.
    Lowe, Michael C.
    Olson, Brian
    Martinez, Anthony
    Hammons, Jacklyn
    Delman, Keith A.
    Yushak, Melinda Lynne
    Allor, Melanie
    Reilly, Christine A.
    Mallow, Crystal L.
    Evans, Elizabeth E.
    Fisher, Terrence Lee
    Lesinski, Gregory B.
    Kudchadkar, Ragini Reiney
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [19] Neoadjuvant vidutolimod and nivolumab in high-risk resectable melanoma: A prospective phase II trial
    Davar, Diwakar
    Morrison, Robert M.
    Dzutsev, Amiran K.
    Karunamurthy, Arivarasan
    Chauvin, Joe-Marc
    Amatore, Florent
    Deutsch, Julie S.
    Das Neves, Rodrigo X.
    Rodrigues, Richard R.
    McCulloch, John A.
    Wang, Hong
    Hartman, Douglas J.
    Badger, Jonathan H.
    Fernandes, Miriam R.
    Bai, Yulong
    Sun, Jie
    Cole, Alicia M.
    Aggarwal, Poonam
    Fang, Jennifer R.
    Deitrick, Christopher
    Bao, Riyue
    Duvvuri, Umamaheswar
    Sridharan, Shaum S.
    Kim, Seungwon W.
    Choudry, Haroon A.
    Holtzman, Matthew P.
    Pingpank, James F.
    O'Toole, James Patrick
    DeBlasio, Richelle
    Jin, Yang
    Ding, Quanquan
    Gao, Wentao
    Groetsch, Christopher
    Pagliano, Ornella
    Rose, Amy
    Urban, Corey
    Singh, Jagjit
    Divarkar, Prajan
    Mauro, David
    Bobilev, Dmitri
    Wooldridge, James
    Krieg, Arthur M.
    Fury, Matthew G.
    Whiteaker, Jeffrey R.
    Zhao, Lei
    Paulovich, Amanda G.
    Najjar, Yana G.
    Luke, Jason J.
    Kirkwood, John M.
    Taube, Janis M.
    CANCER CELL, 2024, 42 (11) : 1898 - +
  • [20] ARF to remain the same for 2022 (vol 231, pg 611, 2021)
    Holland, C.
    BRITISH DENTAL JOURNAL, 2022, 232 (07) : 436 - 436
12345